Cargando…

OPCML, a novel systems regulator of tyrosine kinase signaling in ovarian and other cancers

Detalles Bibliográficos
Autor principal:	Gabra, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327102/ http://dx.doi.org/10.1186/1897-4287-10-S2-A34

Ejemplares similares

OPCML Methylation and the Risk of Ovarian Cancer: A Meta and Bioinformatics Analysis
por: Shao, Yang, et al.
Publicado: (2021)

Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions
por: Birtley, James R., et al.
Publicado: (2019)

OPCML is hypermethylated in a subset of patients with metaplastic changes in their esophagus
por: Castaño-Rodríguez, Natalia, et al.
Publicado: (2018)

Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer
por: Xing, Xiangbin, et al.
Publicado: (2017)

Design and profile of low-molecular-weight receptor tyrosine kinase inhibitors for antiangiogenic therapy
por: Wood, JM
Publicado: (2001)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Role of extracellular signal-related kinase (Erk) 1 in the regulation of neuroinflammation
por: Bendix, I, et al.
Publicado: (2009)

Proteomic identification of the tyrosine phosphatase SHP1 as a novel LMP1 interaction partner, which mediates autoregulation of LMP1 signaling
por: Griese, J, et al.
Publicado: (2009)

OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation
por: Cui, Yan, et al.
Publicado: (2008)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Integrated genomic analysis and functional characterisation of novel oncogenes in ovarian cancer
por: Davis, SJ, et al.
Publicado: (2012)

Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer
por: Wang, Bi, et al.
Publicado: (2017)

Correction: OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation
por: Cui, Yan, et al.
Publicado: (2008)

B cell antigen receptor-induced plasma membrane recruitment of the SH2 domain-containing inositol phosphatase is mediated by the protein tyrosine kinases Lyn and Syk
por: Engelke, M, et al.
Publicado: (2009)

The Australian Ovarian Cancer Study
por: Traficante, N, et al.
Publicado: (2012)

Pathological diagnosis of ovarian cancer
por: High, Hilda, et al.
Publicado: (2012)

Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases
por: Wasenang, Wiphawan, et al.
Publicado: (2019)

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients
por: Thompson, ER, et al.
Publicado: (2012)

Calmodulin kinase II regulates amphetamine-induced reverse transport in dopamine and serotonin transporters
por: Steinkellner, Thomas, et al.
Publicado: (2012)

Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
por: Yu, Yu, et al.
Publicado: (2019)

Grainyhead like 3 – a newly identified TNFalpha regulated transcription factor – is regulated by the Src kinases & NO
por: Lukosz, M, et al.
Publicado: (2009)

Effect of tyrosine ingestion on cognitive function and load carriage performance in the heat
por: Coull, Nicole, et al.
Publicado: (2015)

BY-kinases: Protein tyrosine kinases like no other
por: Hajredini, Fatlum, et al.
Publicado: (2022)

Reclassifying ovarian cancer: origins, subtypes and resistance to therapy
por: Bowtell, DDL
Publicado: (2012)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

Cancer predisposing BARD1 mutations in breast-ovarian cancer families
por: Ratajska, Magdalena, et al.
Publicado: (2012)

The unifying mechanism in the initiation and prevention of breast and other human cancers
por: Cavalieri, E, et al.
Publicado: (2009)

Mixed linage kinase 3 functions as a cGMP-dependent protein kinase I alpha substrate and regulates blood pressure and cardiac remodeling in vivo
por: Calamaras, Timothy, et al.
Publicado: (2015)

A novel BRCA2 gene mutation, 4081 insA, in a Finnish breast/ovarian cancer family associated with favourable clinical course
por: Hartikainen, J, et al.
Publicado: (2000)

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
por: Li, Chuanzhou, et al.
Publicado: (2018)

Targeting sphingosine kinase 1 with LNA oligonucleotides in gastric cancer
por: Füreder, Thorsten, et al.
Publicado: (2008)

BSCI-22. IDENTIFICATION OF ACTIONABLE TYROSINE KINASE-REGULATED NETWORKS REQUIRED FOR LUNG AND BREAST CANCER BRAIN METASTASIS
por: Pendergast, Ann Marie, et al.
Publicado: (2019)

Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study
por: Hung, J, et al.
Publicado: (2012)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Swiprosin 1 – regulator of proximal BCR signaling
por: Kroczek, C, et al.
Publicado: (2009)

Model cell systems representing expression regulation and signal transduction of thymic stromal lymphopoietin (TSLP) in the development of asthmatic symptoms
por: Wohlmann, A, et al.
Publicado: (2009)

Setting up an efficient and reliable screening method for novel c-Jun N-terminal kinase substrates
por: Kallunki, T, et al.
Publicado: (2000)

Differential regulation of mitogenic activated protein kinases by thymosin β4 sulphoxide (Tb4SO)
por: Junghae, M, et al.
Publicado: (2004)

Functional polymorphisms in the TERT promoter are associated with risk of serious ovarian and breast cancer
por: Beesley, Jonathan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3rihrogusi09j1418cga7jbdpt